A5047305563- Endometrial and Cervical Cancer Treatments
- Cervical Cancer and HPV Research
- Ovarian cancer diagnosis and treatment
- Cancer Immunotherapy and Biomarkers
- Colorectal and Anal Carcinomas
- Uterine Myomas and Treatments
- Endometriosis Research and Treatment
- Pregnancy-related medical research
- Minimally Invasive Surgical Techniques
- Intraperitoneal and Appendiceal Malignancies
- Cutaneous Melanoma Detection and Management
- Renal cell carcinoma treatment
- Colorectal Cancer Treatments and Studies
- Appendicitis Diagnosis and Management
- Maternal and Perinatal Health Interventions
- Surgical Simulation and Training
- Maternal and fetal healthcare
- PARP inhibition in cancer therapy
- Lung Cancer Treatments and Mutations
- Vascular anomalies and interventions
- Management of metastatic bone disease
- Pregnancy and preeclampsia studies
- Soft tissue tumors and treatment
- Anatomy and Medical Technology
- Reconstructive Surgery and Microvascular Techniques
Ehime University
2018-2024
Ehime University Hospital
2019-2024
Matsuyama University
2022
Ehime Prefectural Central Hospital
2017
The Cancer Institute Hospital
2014-2015
Japanese Foundation For Cancer Research
2015
Pembrolizumab plus chemotherapy with or without bevacizumab demonstrated prolonged progression-free survival (PFS) and overall (OS) versus in patients persistent, recurrent, metastatic cervical cancer the phase 3, randomized, double-blind, placebo-controlled KEYNOTE-826 study. We report outcomes enrolled Japan. Patients received pembrolizumab 200 mg placebo Q3W for up to 35 cycles (paclitaxel 175 mg/m2 + cisplatin 50 carboplatin AUC 5) 15 mg/kg. Dual primary endpoints were PFS per RECIST...
In the global phase 3 Study 309/KEYNOTE-775 (NCT03517449) at first interim analysis, lenvatinib+pembrolizumab significantly improved progression-free survival (PFS), overall (OS), and objective response rate (ORR) versus treatment of physician's choice chemotherapy (TPC) in patients with previously treated advanced/recurrent endometrial cancer (EC). This exploratory analysis evaluated outcomes enrolled East Asia time prespecified final analysis.
To compare pregnancy outcomes between women with gestational diabetes mellitus (GDM) diagnosed early and late in Japan.
Study 309/KEYNOTE-775 is a phase 3 open-label, randomized trial of lenvatinib plus pembrolizumab versus treatment physician's choice (TPC) in patients with advanced endometrial cancer progression after platinum-based therapy. Primary endpoints superiority for were met progression-free survival (PFS) and overall (OS) all-comers (ie, regardless mismatch repair [MMR] status) MMR proficiency (pMMR). We present results the Japanese subset. Patients to oral 20 mg/day intravenous 200 mg every weeks...
Abstract Background In the phase 3 EMPOWER‐Cervical 1/GOG‐3016/ENGOT‐cx9 study, cemiplimab significantly improved overall survival (OS) versus chemotherapy for patients with recurrent or metastatic cervical cancer who progressed after first‐line platinum‐based chemotherapy. We present a post hoc subgroup analysis of enrolled in Japan. Methods Patients were regardless programmed cell death‐ligand 1 status and randomized 1:1 to 350 mg intravenously every weeks investigator's choice...
<h3>Background</h3> The standard treatment for stage IB–IIB cervical cancer is radiotherapy or radical hysterectomy; after hysterectomy, adjuvant concurrent chemoradiotherapy recommended patients with high risk factors. However, can cause severe gastrointestinal and urinary toxicity. <h3>Primary Objective</h3> To assess whether postoperative chemotherapy not inferior to overall survival in cancer. <h3>Study Hypothesis</h3> Adjuvant will reduce toxicities. <h3>Trial Design</h3> Patients...
(Abstracted from Lancet 2024;403:1341–1350) Prognosis for locally advanced cervical cancer is poor, with 5-year progression-free survival (PFS) and overall ranging 47% to 80%. For the past several decades, treatment has included external beam radiotherapy concurrent chemotherapy followed by brachytherapy, novel therapeutic options are needed.
In most patients, stage IVB cervical cancer is incurable, and the outcomes are poor. There significant individual variation in patients with cancer, whom standard treatment has not been well defined. This study aims to review discuss strategies cancer.From January 1, 1992, December 31, 2011, we retrospectively reviewed data of who were given a diagnosis at Department Gynecology Cancer Institute Hospital.A total 111 enrolled. At time analysis, median overall survival (OS) was 16.6 months...
The introduction of laparoscopic surgery has also been beneficial for patients with gynecological malignancies. In this respect, surgeons should receive related training in the context human resource development. Hands‑on was introduced using Thiel‑embalmed cadavers (THCs) 2014. To determine usefulness THCs, they were evaluated terms tissue color, consistency and operative tactility, among others, compared vivo sessions THCs held a total 11 times at Ehime University Graduate School Medicine...
Similar to primary debulking surgery, complete resection of all macroscopic diseases during interval surgery (IDS) is the objective while using neoadjuvant chemotherapy followed by IDS for advanced ovarian, fallopian tube, and peritoneal cancers. However, most patients develop recurrent disease even after cytoreduction IDS. This study aims identify recurrence patterns cancers in who underwent IDS.We retrospectively reviewed data with stage III or IV were treated at our hospital from January...
The purpose of this study was to analyze the prognosis for endometrial cancer patients treated with systematic pelvic and para-aortic lymphadenectomy (PLA PALA) followed by platinum-based chemotherapy.From 1994 2004, in Cancer Institute Hospital, 502 who were surgically PLA PALA enrolled study. Their clinicopathological features retrospectively reviewed.One hundred ninety-one (38.0%) received adjuvant chemotherapy. Lymph node (LN) metastasis observed 80 (15.9%) patients, pelvic-only LN 27...
We have developed a collaborative hospital-based approach to monitoring the impact of human papillomavirus vaccine on cervical cancer, its precursor lesions and type-specific prevalence in Japan. The will be conducted for total period 21 years women aged <40 who are newly diagnosed with invasive intraepithelial neoplasia or adenocarcinoma situ at participating institutes. Women monitored determine their history papillomavirus-genotyped each year. primary endpoint is papillomavirus16/human...
In the global, randomized, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 (NCT04221945) study, pembrolizumab (pembro) + concurrent chemoradiotherapy (CCRT) showed a statistically significant improvement over placebo (pbo) CCRT in PFS (median PFS, not reached either group; hazard ratio [HR], 0.70 [95% CI, 0.55–0.89]; P=0.0020) and favorable trend for improved OS vs pbo HR, 0.73 0.49–1.07]) patients with high-risk locally advanced cervical cancer (LACC) at first interim analysis. We present results...
'Polypoid endometriosis' is a rare variant of endometriosis. We describe case an extremely large polypoid endometriosis mimicking malignant tumor. A 37-year-old nulliparous woman was referred due to the rapid growth endometriotic cyst ovary and high serum CA125 level. MRI revealed solid components in pelvic mass. These preoperative clinical data were compatible with ovarian carcinoma. frozen section tumor biopsy showed as if adenosarcoma, but finally diagnosis decidual change made on...
<h3>Objective</h3> The aim of this study was to identify the risks and benefits stepladder V-Y advancement medial thigh flap for vulvovaginal reconstruction in comparison direct skin closure. <h3>Methods</h3> Fifty-four patients with vulvar cancer treated our hospital between 1992 2013 were enrolled study. cohort group (group A) consisted 25 who underwent surgery from August 2006 until April 2013. During period, we changed surgical paradigm incorporate reconstructive plastic immediately...
目的 : 子宮頸部上皮内腺癌 (AIS) と診断確定した症例の術前細胞診の診断精度を後方視的に検討した. 方法 2005~2012 年, 円錐切除術または子宮全摘出術で AIS と病理組織で確定診断した 65 例を対象とした. 13 例は従来法に加え液状化検体細胞診でも判定した. 成績 術前細胞診の結果は, NILM 3 例, ASC-US 2 LSIL 1 ASC-H AGC 5 HSIL 7 (CIS) 8 16 SCC ADC 21 例. 術前細胞診上 と診断されたのは 例であり 24.6%にすぎず, 特に 例 (10.7%) が (moderate) 以下と判定され, 過小評価であった. LBC 法でも の正診率は従来法と変わらなかった. 術前組織診にて, 高度異形成以上または 以上と診断なく, 円錐切除術を施行した症例は 11 (16.9%) あり, このうち 例で 1~2 年持続していた. 結論 の細胞診の診断は困難で慎重な対応が必要である. が持続する場合, HPV タイピング検査と診断確定のために円錐切除術を考慮すべきと考えられた.
<h3>Introduction/Background</h3> It is concerned that the tumor dormancy effect of bevacizumab might prolong disease-free interval (DFI) regardless platinum sensitivity, and lead to poorer outcome especially for patients recurrent in partially platinum-sensitive period defined as free (PFI) 6 12 months. We retrospectively investigated relevance PFI response rate ovarian cancer after chemotherapy with concurrent maintenance bevacizumab. <h3>Methodology</h3> Patients received platinum-based...